Shunji Haruta
Technik-/Wissenschafts-/F&E-Leiter bei SHIN NIPPON BIOMEDICAL LABORATORIES, LTD.
Aktive Positionen von Shunji Haruta
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2011 | - |
| SATSUMA PHARMACEUTICALS, INC. | Direktor/Vorstandsmitglied | 08.06.2023 | - |
Karriereverlauf von Shunji Haruta
Statistik
International
| Japan | 2 |
| Vereinigte Staaten | 2 |
Operativ
| Chief Tech/Sci/R&D Officer | 1 |
| Director/Board Member | 1 |
Sektoral
| Commercial Services | 2 |
| Health Technology | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. | Commercial Services |
| Private Unternehmen | 1 |
|---|---|
Satsuma Pharmaceuticals, Inc.
 Satsuma Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It develops novel therapeutic products for the acute treatment of migraines. Its product candidate, STS101, is a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, or DHE, which is designed to be self-administered with a proprietary pre-filled, single-use, nasal delivery device. The company was founded by John Kollins on June 21, 2016 and is headquartered in Durham, NC. | Health Technology |
- Börse
- Insiders
- Shunji Haruta
- Erfahrung